TGFB1 and COVID-19: Moreover, the possible inhibitory effect of enoxacin on TGF-β signaling is interesting because TGF-β signaling (i) drives the chronic adaptive immune responses in patients with ARDS88, resulting in rapid and massive edema and fibrosis in these patients (for this reason, its blockade has been suggested as a potential treatment of COVID-19)89 and (ii) increases FURIN expression in well-differentiated primary human bronchial epithelial cells90 (therefore, its blockade may attenuate the SARS-CoV-2 entry into the cells).